FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480208.407APPLICATION NO.
09/896,811INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS

Thomas D. Madden et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
AB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


AC	Abraham, S. A., K. Edwards, et al. "An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes." <i>J Control Release</i> 96(3): 449-61, 2004.
AD	Apostolidou, E., G. Garcia-Manero, et al. "Phase I Study of OSI-211, a Novel Liposomal Topoisomerase I (Topo I) Inhibitor, in Patients with Refractory Leukemia." <i>Blood</i> , 2002. Abstract #4575.
AE	Biloti, D. N., A. Santana Maria Helena, et al. "Lipid membrane with low proton permeability." <i>Biochim Biophys Acta</i> 1611(1-2): 1-4, 2003.
AF	Bom, D., D. P. Curran, et al. "The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity." <i>J Med Chem</i> 43(21): 3970-80, 2000.
AG	Bom, D., D. P. Curran, et al. "The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity." <i>J Control Release</i> 74(1-3): 325-33, 2001.
AH	Burke, T. G. and D. Bom, "Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo." <i>Ann N Y Acad Sci</i> 922: 36-45, 2000.
AI	Burke, T. G. and X. Gao "Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine." <i>J Pharm Sci</i> 83(7): 967-9, July 1994.
AJ	Burke, T. G., E. Staibus Alfred, et al. "Liposomal stabilization of Camptothecin lactone ring." <i>J Am Chem Soc</i> 114:8318-8319, 1992.
AK	Burke, T. G., Z. Mi, et al. "Liposomal stabilization of camptothecins." <i>Proc Amer Assoc Cancer Res.</i> 35:416, March 1994. Abstract #2479
AL	Chou, T.-H., S.-C. Chen, et al. "Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method." <i>Journal of Bioscience and Bioengineering.</i> 95(4):405-408, 2003
AM	Chow, D. S. L., G. Chen, et al. "Liposomal camptothecin and 9-nitro-camptothecin: Formulation, pharmacokinetics and preclinical anti-tumor activity." <i>Proceedings of the Controlled Release Society</i> , pp. 919-920, 1997.

EXAMINER

DATE CONSIDERED

7/10/2005

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.407	APPLICATION NO. 09/896,811
INVENTOR'S DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Thomas D. Madden et al.	
		FILING DATE June 29, 2001	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS


*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
BB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

hcl	BC	Chow, D. S., L. Gong, et al. "Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin." <i>Ann N Y Acad Sci</i> 922:164-74, 2000.
	BD	Clements, M. K., C. B. Jones, et al. "Antiangiogenic potential of camptothecin and topotecan." <i>Cancer Chemother Pharmacol</i> 44(5): 411-6, 1999.
	BE	Clements, M. K., S. Wasi, et al. "Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro." <i>Anticancer Drugs</i> 7(8): 851-7, 1996.
	BF	Colbern, G. T., D. J. Dykes, et al. "Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts." <i>Clin Cancer Res</i> 4(12): 3077-82, December 1998.
	BG	Daoud, S. S., M. I. Fetouh, et al. "Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts." <i>Anticancer Drugs</i> 6(1): 83-93, 1995.
	BH	Dunton, C. J. "New options for the treatment of advanced ovarian cancer." <i>Semin Oncol</i> 24(1 Suppl 5):S5-2-S5-11, February 1997.
	BI	El-Kareh, A. W. and T. W. Secomb "Theoretical models for drug delivery to solid tumors." <i>Crit Rev Biomed Eng</i> 25(6): 503-571, 1997.
	BJ	Emerson, D. L. "Liposomal delivery of camptothecins." <i>Pharmaceutical Science and Technology Today</i> 3(6): 205-209, June 2000.
	BK	Emerson, D. L., N. Amirgahari, et al. "NX-211, a liposomal formulation of lurtotecan demonstrates enhanced pharmacokinetic and antitumor activity." <i>Proc Amer Assoc Cancer Res</i> 39: 278, March 1998. Abstract #1897.
	BL	Emerson, D. L., R. Bendele, et al. "Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan." <i>Clin Cancer Res</i> 6(7): 2903-12, July 2000.
	BM	Emerson, D., A. Gray, et al. "The topoisomerase I inhibitor, NX211 demonstrates significant in vivo activity against human acute myeloid leukemia (AML) engrafted in SCID mice." <i>Blood</i> , 1999. Abstract #4223.

EXAMINER 	DATE CONSIDERED 7/10/05
---	----------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.407	APPLICATION NO. 09/896,811
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Thomas D. Madden et al.	
		FILING DATE June 29, 2001	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS


*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA						


FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
CB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CC	Erickson-Miller, C. L., R. D. May, et al. "Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro." <i>Cancer Chemother Pharmacol</i> 39(5): 467-72, 1997.
CD	Garcia-Carbonero, R. and J.G. Supko "Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins." <i>Clin Cancer Res</i> 8(3): 641-661, March 2002.
CE	Gelmon, K., H. Hirte, et al. "A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers." <i>Invest New Drugs</i> 22(3): 263-75, 2004.
CF	Giles, F. J., M. S. Tallman, et al. "Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia." <i>Cancer</i> 100(7): 1449-58, April 2004.
CG	Giles, F., M. Tallman, et al. "Phase I and pharmacokinetic study of OSI-211, a liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia." <i>Blood</i> , p. 2516, 2003. Abstract #4732.
CH	Guo, W., A. Ahmad, et al. "Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38)." <i>J Chromatogr B</i> 791(1-2): 85-92, 2003.
CI	Hatefi, A. and B. Amsden "Camptothecin delivery methods." <i>Pharm Res</i> 19(10):1389-1399, October 2002.
CJ	Khan, S., A. Ahmad, et al. "A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38)." <i>Biomedical chromatography - BMC</i> 17(8): 493-9, 2003.

EXAMINER 	DATE CONSIDERED 7/10/2005
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	



FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.407	APPLICATION NO. 09/896,811
INFORMATION DISCLOSURE STATEMENT (See several sheets if necessary)		APPLICANTS Thomas D. Madden et al.	
		FILING DATE June 29, 2001	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA						

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
DB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DC	Knight, V., E. S. Kleinerman, et al. "9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice." <i>Ann N Y Acad Sci</i> 922: 151-63, 2000.
DD	Knight, V., N. Koshkina, et al. "Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice." <i>Trans Am Clin Climatol Assoc</i> 111: 135-45, 2000.
DE	Knight, V., N. V. Koshkina, et al. "Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice." <i>Cancer Chemother Pharmacol</i> 44(3): 177-86, 1999.
DF	Koshkina, N. V., B. E. Gilbert, et al. "Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice." <i>Cancer Chemother Pharmacol</i> 44(3): 187-92, 1999.
DG	Koshkina, N. V., E. S. Kleinerman, et al. "9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice." <i>Clin Cancer Res</i> 6(7): 2876-80, 2000.
DH	Koshkina, N. V., V. Knight, et al. "Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO ₂ -enriched air: pharmacokinetic studies." <i>Cancer Chemother Pharmacol</i> 47(5): 451-6, 2001.
DI	Lei, S., P.-Y. Chien, et al. "Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice." <i>Anticancer Drugs</i> 15(8): 773-8, 2004.
DJ	Liu, J. J., R. L. Hong, et al. "Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation." <i>Anticancer Drugs</i> 13(7): 709-17, 2002.
DK	Liu, X., B. C. Lynn, et al. "A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs." <i>J Am Chem Soc</i> 124(26): 7650-1, 2002.

EXAMINER	DATE CONSIDERED
	7/10/05

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-144 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480208.407		APPLICATION NO. 09/896,811	
INFORMATION DISCLOSURE STATEMENT (Use separate sheets if necessary)				APPLICANTS Thomas D. Madden et al.		GROUP ART UNIT 1614	
FILING DATE June 29, 2001							
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	EB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	EC			Loos, W. J., D. Kehrer, et al. "Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography." <i>J Chromatogr B</i> 738(1): 155-63, 2000.			
	ED			Loos, W. J., J. Verweij, et al. "Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan." <i>Clin Cancer Res</i> 8(3): 856-62, March 2002.			
	EE			Lundberg, B. B. "Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions." <i>Anticancer Drug Des</i> 13(5): 453-61, 1998.			
	EF			Luo, J. D., Z. Q. Ma, et al. "[Studies on polyphase liposome of camptothecin, PL-CSA]." <i>Yao xue xue bao = Acta pharmaceutica Sinica</i> 19(1): 63-8, 1984.			
	EG			Lynam, E., D. J. Landfair, et al. "Camptothecin analogue efficacy in vitro: Effect of liposomal encapsulation of GI147211C (NX211)." <i>Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents</i> 6:51-62, 1999.			
	EH			MacKenzie, M. J., H. W. Hirte, et al. "A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers." <i>Ann Oncol</i> 15(4): 665-70, 2004.			
	EI			Maliepaard, M., M. A. Van Gastelen, et al. "Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918." <i>Clin Cancer Res</i> 7(4): 935-941, April 2001.			
	EJ			Meerum, T. J. M., J. H. M. Schellens, et al. "Clinical pharmacology of anticancer agents in relation to formulations and administration routes." <i>Cancer Treat Rev</i> 25(2): 83-101, 1999.			
	EK			Messerer, C. L., E. C. Ramsay, et al. "Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer." <i>Clin Cancer Res</i> 10(19): 6638-49, October 2004.			
	EL			Mi, Z. and T. G. Burke "Differential interactions of camptothecin lactone and carboxylate forms with human blood components." <i>Biochemistry</i> 33(34): 10325-36, 1994.			
EXAMINER				DATE CONSIDERED			
				7/6/05			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							



FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.407	APPLICATION NO. 09/896,811
INFORMATIONAL CLOSURE STATEMENT (Indicate on several sheets if necessary)		APPLICANTS Thomas D. Madden et al.	
		FILING DATE June 29, 2001	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						


FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
FB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

al	FC	Proulx, M. E., A. Desormeaux, et al. "Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin." <i>Antimicrob Agents Chemother</i> 45(9): 2623-7, 2001.
	FD	Proulx, M. E., J. F. Marquis, et al. "Incorporation of camptothecin into liposomes: A new approach for the treatment of leishmaniasis." <i>Abstracts of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy</i> , San Francisco, 1999. Abstract 1856.
	FE	Sadzuka, Y. "Effective prodrug liposome and conversion to active metabolite." <i>Curr Drug Metab</i> 1(1): 31-48, 2000.
	FF	Sadzuka, Y., S. Hirotsu, et al. "The study of polyethyleneglycol-coated liposomes containing CPT-11." <i>J Liposome Res</i> 7(2&3): 241-260, 1997.
	FG	Sadzuka, Y., S. Hirotsu, et al. "Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11." <i>Cancer Lett</i> 127(1-2): 99-106, 1998.
	FH	Sadzuka, Y., S. Hirotsu, et al. "Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38." <i>Jpn J Cancer Res</i> 90(2): 226-32, February 1999.
	FI	Seiden, M. V., F. Muggia, et al. "A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer." <i>Gynecol Oncol</i> 93(1): 229-32, 2004.
	FJ	Stano, P., S. Bufali, et al. "Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method." <i>J Liposome Res</i> 14(1-2): 87-109, 2004.
	FK	Subramanian, D. and M. T. Muller "Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan." <i>Oncol Res</i> 7(9): 461-9, 1995.
	FL	Tardi, P., E. Choice, et al. "Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models." <i>Cancer Res</i> 60(13): 3389-93, July 2000.
	FM	Tomkinson, B. E., E. Brown, et al. "In vivo evaluation of NX 211 in combination with cisplatin, 5-FU, and paclitaxel." <i>Proc Amer Assoc Cancer Res</i> 41:144, March 2000. Abstract #917.

EXAMINER 	DATE CONSIDERED 7/10/05
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480208.407APPLICATION NO.
09/896,811

APPLICANTS

Thomas D. Madden et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
GB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

GC	Tomkinson, B., R. Bendele, et al. "OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL." <i>Leukemia Research</i> 27(11): 1039-50, 2003.
GD	Verschraegen, C. F., B. E. Gilbert, et al. "Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs." <i>Ann N Y Acad Sci</i> 922: 352-4, 2000.
GE	Verschraegen, C. F., B. E. Gilbert, et al. "Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies." <i>Clin Cancer Res</i> 10(7): 2319-26, April 2004.
GF	Verschraegen, C. F., K. Jaeckle, et al. "Alternative administration of camptothecin analogues." <i>Ann N Y Acad Sci</i> 922: 237-46, 2000. Abstract only
GG	Zhang, J. A., T. Xuan, et al. "Development and characterization of a novel liposome-based formulation of SN-38." <i>Int J Pharm</i> 270(1-2): 93-107, 2004.
GH	Zhang, Q. M., X. Q. Gu, et al. "[A method for determining the encapsulation ratio of camptothecin in polyphase liposome and studies on its leakage property]." <i>Yao xue xue bao = Acta Pharmaceutica Sinica</i> 22(12): 918-22, 1987.
GI	Zufia, L., A. Aldaz, et al. "Separation methods for camptothecin and related compounds." <i>J Chromatogr B</i> 764(1-2): 141-159, 2001.
GJ	Zunino, F., S. Dallavalle, et al. "Current status and perspectives in the development of camptothecins." <i>Curr Pharm Des</i> 8(27): 2505-2520, 2002.
GK	Desjardins, J. P., E. A. Abbott, et al. (2001). "Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice." <i>Anticancer Drugs</i> 12(3): 235-45, March 2001.
GL	Begu, S., C. Tourne-Petel, et al. "Spectrofluorimetry study of interaction of camptothecin with liposomal bilayer." <i>Luminescence</i> 15:78-79, 2000.
GM	Bell, C. B., D. J. Landfair, et al. "Topoisomerase I (TOPO-1) modulation by liposomal GI147211 (NX211)." <i>Proc Amer Assoc Cancer Res</i> 41, p. 773, March 2000. Abstract #4915.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.407	APPLICATION NO. 09/896,811
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Thomas D. Madden et al.	
		FILING DATE June 29, 2001	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HA						


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HB	Bevins, R. L., D. Bom, et al. "Tumor cell cycle disruption and apoptosis induced by DB-67, a highly lipophilic camptothecin displaying improved human blood stability." <i>Proc Amer Assoc Cancer Res</i> 42, p. 102, March 2001. Abstract #554.
HC	Bom, D. C., J. Zhang, et al. "The structural basis of camptothecin loading and retention in liposomal drug carriers." <i>Proc Amer Assoc Cancer Res</i> 42:374, March 2001. Abstract #2016.
HD	Burke, T. G., A. J. Chavan, et al. "Development and evaluation of a liposomal formulation of highly lipophilic 7-t-butyldimethylsilyl-10-hydroxy-camptothecin." <i>Proc Amer Assoc Cancer Res</i> 40, March 1999. Abstract #752.
HE	Burke, T. G., D. Subramanian, et al. "Enhanced bloodstream stability and in vitro activity of topotecan formulated in liposomes." <i>Pharm Res</i> 11(10):S-323, October 1994. Abstract # PDD 7596.
HF	Burke, T. G., S. Gao Xiang, et al. "Liposomal stabilization of the lactone ring of camptothecin anticancer drugs." <i>Pharm Res</i> 10(10):S-220, October 1993. Abstract # PDD 7483.
HG	Burke, T. G., X. Liu, et al. "A versatile pro-drug approach for the liposomal core loading of camptothecin anticancer drugs." <i>Proc Amer Assoc Cancer Res</i> 43, March 2002. Abstract #5731.
HH	Burke, T. G., Z. Mi, et al. (1994). "Liposomal formulations of camptothecins for cancer treatment." Abstracts of Papers American Chemical Society, In <i>Proceedings of the 208th ACS National Meeting</i> , Washington, DC, August 21-25, 1994. Abstract #50
HI	Cao, Z. and C. Giovannella Beppino, "Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs." <i>Official Gazette of the United States Patent and Trademark Office Patents</i> 1256(1):372, March 2002. US Patent 6,352,996 B1.
HJ	Chavan, A. J., K. A. Fraley, et al. "A comparative study of the human blood stability characteristics of remote-loaded liposomal carriers containing clinically-relevant camptothecins." <i>Proc Amer Assoc Cancer Res</i> 40:417, March 1999. Abstract #6019.
HK	Chen, G., A. Double John, et al. "Characterization of liposomal mimetic formulations for selective targeting." <i>Pharm Res</i> 13:S-161, September 1996. Abstract # PPDM 8345.
HL	Chen, G., W. Barry Brian, et al. "Pharmacokinetic evaluation of liposomal camptothecin." <i>Pharm Res</i> 13(9):S-479, September 1996.

EXAMINER

DATE CONSIDERED


* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).


FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.407	APPLICATION NO. 09/896,811
INFORMATION DISCLOSURE STATEMENT (Use additional sheets if necessary)			APPLICANTS Thomas D. Madden et al.	
			FILING DATE June 29, 2001	GROUP ART UNIT 1614


U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						
	IB						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	IC	Cherian, M. "Lyophilizate of lipid complex of water insoluble camptothecins." <i>Official Gazette of the United States Patent and Trademark Office Patents</i> 1269(3), April 2003. U.S. Patent 6,548,071 B1.
	ID	Chien, P.-Y., S. Sheikh, et al. "Cytotoxicity evaluation of a liposome-based formulation of SN38 in human and murine cancer cell lines." <i>Proc Amer Assoc Cancer Res</i> 44:314, July 2003. Abstract #1607.
	IE	Choice, E., M. B. Bally, et al. "Delivery of topotecan using liposomes: Drug loading into liposomes and drug and carrier pharmacokinetics in female Balb/c mice." <i>Proc Amer Assoc Cancer Res</i> 40, March 1999. Abstract #753.
	IF	Chow, D. S. L., G. Chen, et al. "Pharmacokinetics and in vivo antitumor activity of liposomal encapsulated camptothecin and its analog." <i>Proc Amer Assoc Cancer Res</i> 38, March 1997.
	IG	Cortesi, R., E. Esposito, et al. "Formulation study for the antitumor drug camptothecin: Liposomes, micellar solutions and a microemulsion." <i>Int J Pharm</i> 159:95-103, 1997.
	IH	Cortesi, R., E. Esposito, et al. "Liposomes, micelles and microemulsions as new delivery systems for camptothecin." <i>Eur J Pharm Sci</i> 6(Supp. 1):S3, 1998. Abstract #12
	II	Dallavalle, S., L. Merlini, et al. "Perspectives in camptothecin development." <i>Expert Opinion on Therapeutic Patents</i> 12(6):837-844, 2002.
	IJ	Daoud, S. S., M. I. Fetouh, et al. (1993). "Multilamellar liposomes as a delivery system for camptothecin (NSC 94600) and 9-aminocamptothecin (NSC 603071)." in <i>Proc Amer Assoc Cancer Res</i> . Orlando, FL, May 19-22, 1993, 367. Abstract #2188
	IK	Desjardins, J. P., D. L. Emerson, et al. "Biodistribution of NX 211, liposomal GI147211, in tumor bearing mice." <i>Proc Amer Assoc Cancer Res</i> 41:702, March 2000. Abstract #4467.
	IL	Emerson, D. L., N. Amirghahari, et al. "Enhanced in vivo antitumor efficacy of the liposome formulated topoisomerase I inhibitor Lurtotecan." <i>Proc Amer Assoc Cancer Res</i> 40:113, March 1999. Abstract #751
	IM	Emerson, D. L., R. Bendele, et al. "In vivo antitumor efficacy of liposomal lurtotecan (NX 211) in human xenografts." <i>Proc Amer Assoc Cancer Res</i> 42:100, March 2001. Abstract #545.

EXAMINER 	DATE CONSIDERED 7/10/05
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	

FORM PTO-1449
(REV. 7-80)

MAY 05 2005

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

480208.407

APPLICATION NO.

09/896,811

APPLICANTS

Thomas D. Madden et al.

FILING DATE

June 29, 2001

GROUP ART UNIT

1614

INFORMATION DISCLOSURE STATEMENT
(Include copy of this form with next communication to applicant(s).)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JA						
JB						


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

al	JC	Gelmon, K. A., E. Eisenhauer, et al. "Phase 1 study of NX 211 (liposomal lurtotecan) given as an intravenous infusion on days 1, 2, and 3 every weeks in patients (pts) with solid tumors- An NCIC clinical trials group study." <i>Proc Amer Assoc Cancer Res</i> 41:610, March 2000. Abstract #3879.
	JD	Gilbert, B. E., A. Seryshev, et al. "9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs." <i>Inhal Toxicol</i> 14(2): 185-97, 2002.
	JE	Gong, L., B. C. Giovannella, et al. "Improved lactone stability of 9-nitro-camptothecin in vitro and in vivo by liposomal formulation." <i>Proc Amer Assoc Cancer Res</i> 39:430, March 1998. Abstract #2926
	JF	Gong, L., B. C. Giovannella, et al. "Sustained organ exposure to 9-nitro-camptothecin (9NC) lactone form by liposomal delivery." <i>Proc Amer Assoc Cancer Res</i> 40:417, March 1999. Abstract #2756.
	JG	Gong, L., G. Chen, et al. "Development and characterization of liposomal formulation of 9-nitro-camptothecin." <i>Pharm Res</i> 13:S-162, September 1996. Abstract #6021.
	JH	Haas, H., B. Schulze, et al. "Strong antitumor efficacy of a cationic liposomal camptothecin formulation (LipoCam TM) in the subcutaneous human melanoma A-375 in nude mice." <i>Proc Amer Assoc Cancer Res</i> 44:350-351, July 2003. Abstract # R1793.
	JI	Kamath, N., K. Sarkar Asis, et al. "Therapeutic efficacy of liposome-based formulation of SN38 against leukemia model in CD2F1 mice." <i>Proc Amer Assoc Cancer Res</i> 44, 2 nd Ed., July 2003. Abstract #1784.
	JJ	Khan, S., S. Ali, et al. "Liposome based formulation of SN-38 (LE-SN38): A four-cycle toxicity evaluation in beagle dogs." <i>Toxicological Sciences</i> 72(S-1), March 2003. Abstract #1873.
	JK	Knight, J. V., B. Gilbert, et al. "Small particle liposome aerosols for delivery of anti-cancer drugs." <i>Official Gazette of the United States Patent and Trademark Office Patents</i> 1236(3):2973, July 18, 2000. U.S. Patent 6,090,407.
	JL	Koshkina, N. V., B. E. Gilbert, et al. (1999). "Pharmacokinetics and tissue distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice." <i>Proc Amer Assoc Cancer Res</i> 40:10, March 1999. Abstract #734.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480208.407APPLICATION NO.
09/896,811INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANTS
Thomas D. Madden et al.FILING DATE
June 29, 2001GROUP ART UNIT
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA						
	KB						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

al	KC	Kruszewski, S., A. S. Chavan, et al. (2000). "Comparison of the human blood chemistry of free versus liposomal forms of the clinically-relevant topoisomerase I inhibitor Lurtotecan (GI147221)." <i>Proc Amer Assoc Cancer Res</i> 41:324, March 2000. Abstract #2056.
	KD	Lerchen, H. G. "Camptothecin antitumor agents." <i>Idrugs</i> 2(9):896-906, 1999.
	KE	Loos, W. J., D. F. S. Kehrner, et al. "Clinical pharmacodynamics of liposomal lurtotecan (NX 211): Urinary excretion predicts hematologic toxicity." <i>Proc Amer Assoc Cancer Res</i> 42:102, March 2001. Abstract #551.
	KF	Lopez-Barcons, L. A., J. Zhang, et al. "The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colorectal carcinoma." <i>Proc Amer Assoc Cancer Res</i> 44(2): 348, 2003. Abstract #1782.
	KG	Lynam, E., D. J. Landfair, et al. "Camptothecin analogue efficacy in vitro: Effect of liposomal encapsulated of GI147211C (Lurtotecan) on vitro cytotoxicity for multiple tumor cell types." <i>Proc Amer Assoc Cancer Res</i> 31:421, March 1998.
	KH	Mamot, C., D. C. Drummond, et al. "Liposome-based approaches to overcome anticancer drug resistance." <i>Drug Resistance Updates</i> 6:271-279, 2003.
	KI	Michaelis, U., B. Schulze, et al. "Cationic liposomes (Catioms) to target tumor neovasculature." Abstracts of Papers American Chemical Society, in <i>Proceedings of the 226th ASC National Meeting</i> , New York, September 7-11, 2003.
	KJ	Moynihan Karen, L., L. Emerson David, et al. "Liposomal camptothecin formulations." <i>Official Gazette of the United States Patent and Trademark Office Patents</i> , 2004. U.S. Patent 6,740,335B1.
	KK	Pal, A., S. Sheikh, et al. "Enhanced antitumor efficacy of liposome-based formulation of SN38 against human pancreatic tumor in SCID mice." <i>Proc Amer Assoc Cancer Res</i> , 2003. Abstract #1785.
	KL	Poirot, K., Y. Zou, et al. "Liposomal-camptothecin composed of cationic phospholipids containing unsaturated fatty acids: Formulation and cytotoxicity studies." <i>Proc Amer Assoc Cancer Res</i> 37:300, March 1996. Abstract #2039.
	KM	Sadzuka, Y., S. Hirotsu, et al. "Antitumor effect of CPT-11 encapsulated liposome and conversion to active metabolite." <i>J Liposome Res</i> , pp. 101-102, 1998.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480208.407APPLICATION NO.
09/896,811INFORMATION DISCLOSURE STATEMENT
(Indicate on several sheets if necessary)APPLICANTS
Thomas D. Madden et al.FILING DATE
June 29, 2001GROUP ART UNIT
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION IF APPROPRIATE	
			YES	NO
LB				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LC	Sarkar, A., N. Kamath, et al. "Toxicity evaluation of a liposome-based formulation of SN38 in mice." <i>Toxicol Sci</i> 72(S-1):83, March 2003. Abstract #403.
LD	Semple, S. C., B. L. S. Mui, et al. "Comparative efficacy and therapeutic index of topotecan and liposomal topotecan in murine and human solid tumor models." <i>Proc Amer Assoc Cancer Res</i> 44, July 2003. Abstract #3658.
LE	Semple, S. C., S. K. Klimuk, et al. "Pre-clinical evaluation of liposomal topotecan: Increased efficacy and therapeutic index in murine and human xenograft tumor models compared to free drug." <i>Proc Amer Assoc Cancer Res</i> 42:374, March 2001. Abstract #2015.
LF	Sugarman, S. and R. Perez-Soler "Liposomal camptothecin: Formulation and cytotoxicity against KB cells." <i>Proc Amer Assoc Cancer Res</i> , Orlando, FL, May 19-22, 1993, p. 422. Abstract #2519.
LG	Tanyeli, C., D. Bom, et al. "Formulation and pharmacological characterization of the novel polyamine camptothecin CT-17 encapsulated in low-clearance liposomes." <i>Proc Amer Assoc Cancer Res</i> 42:255, March 2001. Abstract #1379.
LH	Tomkinson, B., E. Brown, et al. (2001). "Efficacy of NX 211 in SCID mouse models of human leukemia." <i>Proc Amer Assoc Cancer Res</i> 42:100, 2001. Abstract #542.
LI	Ulukan, H., D. Roy, et al. "Controlled release of topotecan from thermosensitive liposomes." <i>Proc Amer Assoc Cancer Res</i> 36:308, March 1995. Abstract #1833.
LJ	Yu, N. Y., C. Conway, et al. "STEALTH liposome formulation enhances antitumor efficacy of CKD-602, a topoisomerase I inhibitor, in human tumor xenograft models." <i>Proc Amer Assoc Cancer Res</i> 45: 710, March 2004. Abstract #3069.
LK	Zunino, F. and G. Pratesi "Camptothecins in clinical development." <i>Expert Opin Investig Drugs</i> 13(3): 269-284, 2004.
LL	Madden T. et al., "Encapsulation of Topotecan in Lipid-Based Carrier Systems: Evaluation of Drug Stability and Plasma Elimination in a Murine Model, and Comparison of Antitumor Efficacy Against Murine L1210 and B16", <i>Proceedings from 34th Annual ASCO Meeting</i> , 1998. Abstract #754.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).